US based company, Life Biosciences has announced the closing of a Series B financing round of $50 million.

The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ research and development activities in potential therapeutics to combat age-related decline, and related purposes.

Tristan Edwards, chief executive officer and co-founder, Life Biosciences said, “We are excited by this investor response to our Series B, and the validation it represents. The range of investors in this round includes individuals, family trusts, and other professional investors. We believe this response recognizes the power of our teams and science, and the progress we are making in addressing the pathways of aging.”

Life Biosciences is dedicated to tackling the eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase healthspans and reduce disease for everyone, including companion animals.

Life Biosciences was co-founded in 2017 by renowned scientists and Tristan Edwards. There are six Daughter companies working independently and together within the Life Biosciences research environment.